This trial will test the safety and effectiveness of a new drug, APG-5918, in people with cancer. The drug will be given orally in 28-day cycles. The trial will have two parts: first, a dose escalation to test safety, and second, a dose expansion to test effectiveness.
- Nasopharyngeal Cancer
- Castration-resistant Prostate Cancer
- Stomach Cancer
- Ovarian Clear Cell Carcinoma
- Non-Hodgkin's Lymphoma
- B-Cell Lymphoma
- Epithelioid Sarcoma
1 Primary · 0 Secondary · Reporting Duration: 28 days
2 Treatment Groups
Cohort 1 in Dose expansion
1 of 2
Cohort 2 in Dose expansion
1 of 2
90 Total Participants · 2 Treatment Groups
Primary Treatment: APG-5918 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 13 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||50.0%|
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Frequently Asked Questions
What is the aggregate amount of people who have elected to partake in this experiment?
"Affirmative. According to the information available on clinicaltrials.gov, this medical investigation is actively seeking participants; it was first posted on September 30th 2022 and has been recently updated on November 11th 2022. A total of 90 individuals are needed from 2 trial sites." - Anonymous Online Contributor
Are any openings available for participation in this trial?
"Per the latest information from clinicaltrials.gov, this trial is open and actively recruiting participants. The initial posting took place on September 30th 2022 with a recent update happening November 11th 2022." - Anonymous Online Contributor
Is APG-5918 a potential risk factor to the general population?
"As this is an early Phase I trial, APG-5918's safety was rated at a 1. This assessment is based on limited evidence concerning the drug's effectiveness and its potential to cause harm." - Anonymous Online Contributor